These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 11027803

  • 1. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.
    McCluskie MJ, Davis HL.
    Vaccine; 2000 Oct 15; 19(4-5):413-22. PubMed ID: 11027803
    [Abstract] [Full Text] [Related]

  • 2. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
    McCluskie MJ, Weeratna RD, Davis HL.
    Vaccine; 2001 Mar 21; 19(17-19):2657-60. PubMed ID: 11257405
    [Abstract] [Full Text] [Related]

  • 3. CpG DNA is an effective oral adjuvant to protein antigens in mice.
    McCluskie MJ, Weeratna RD, Krieg AM, Davis HL.
    Vaccine; 2000 Nov 22; 19(7-8):950-7. PubMed ID: 11115721
    [Abstract] [Full Text] [Related]

  • 4. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
    McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.
    FEMS Immunol Med Microbiol; 2002 Feb 18; 32(3):179-85. PubMed ID: 11934561
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
    Diwan M, Tafaghodi M, Samuel J.
    J Control Release; 2002 Dec 13; 85(1-3):247-62. PubMed ID: 12480329
    [Abstract] [Full Text] [Related]

  • 9. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.
    BMC Res Notes; 2017 Jan 26; 10(1):68. PubMed ID: 28126014
    [Abstract] [Full Text] [Related]

  • 10. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM.
    J Immunol; 1998 Jan 15; 160(2):870-6. PubMed ID: 9551923
    [Abstract] [Full Text] [Related]

  • 11. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ, Davis HL.
    J Immunol; 1998 Nov 01; 161(9):4463-6. PubMed ID: 9794366
    [Abstract] [Full Text] [Related]

  • 12. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid.
    Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA.
    Vaccine; 2001 Feb 08; 19(13-14):1636-42. PubMed ID: 11166886
    [Abstract] [Full Text] [Related]

  • 13. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M, Sajadi Tabassi SA, Jaafari MR.
    Int J Pharm; 2006 Aug 17; 319(1-2):37-43. PubMed ID: 16701972
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of different CpG oligodeoxynucleotides with inactivated avian H5N1 influenza virus on mucosal immunity of chickens.
    Fu J, Liang J, Kang H, Lin J, Yu Q, Yang Q.
    Poult Sci; 2013 Nov 17; 92(11):2866-75. PubMed ID: 24135589
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characterization of Immune Responses to an Inactivated Avian Influenza Virus Vaccine Adjuvanted with Nanoparticles Containing CpG ODN.
    Singh SM, Alkie TN, Abdelaziz KT, Hodgins DC, Novy A, Nagy É, Sharif S.
    Viral Immunol; 2016 Jun 17; 29(5):269-75. PubMed ID: 27077969
    [Abstract] [Full Text] [Related]

  • 20. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
    Ioannou XP, Gomis SM, Karvonen B, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S.
    Vaccine; 2002 Nov 22; 21(1-2):127-37. PubMed ID: 12443671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.